Performance of Two Intraocular Lenses With Extended Depth of Vision

January 3, 2022 updated by: Prim. Prof. Dr. Oliver Findl, MBA, Vienna Institute for Research in Ocular Surgery

Performance of Two Non-diffractive Intraocular Lenses With Extended Depth of Vision Set for Mini-monovision

Comparison of the capsular bag performance of two extended depth of vision (EDOF) intraocular lenses (IOLs), the Rayone EMV and the Alcon Acrysof IQ Vivity, in a mini-monovision setting

Study Overview

Status

Recruiting

Conditions

Detailed Description

Spectacle independence is a rising aim in modern cataract surgery. Although bilateral monofocal IOL implantation, aiming for emmetropia leads to high levels of patient satisfaction for distance vision, spectacle dependence for reading and intermediate vision tasks is the usual result.

The option commonly used to achieve spectacle independence in all distances are multifocal intraocular lenses. One concept of multifocality is the trifocal lens. This lens provides good vision in three focal distances: far, intermediate, and near. However, one potential disadvantage of trifocal IOLs is slightly poorer near vision with need for reading gasses for prolonged fine near work and loss of contrast sensitivity in the intermediate distance.

A better intermediate performance concerning contrast vision compared to trifocal IOLs can be reached using enhanced depth of focus (EDOF) lenses. These IOLs have an extended far focus area, which reaches to the intermediate distance, providing high-quality vision over a continuous range of focus, rather than distinct foci with blur in between. In the last years several technologies for EDOF IOLs appeared on the market. The disadvantage compared to monofocal lenses in all of these technologies is the potentially worse contrast sensitivity as well as dysphotopsia.

A new monofocal non-diffractive lens with an extended depth of vision (Rayone EMV) promises an increased range of functional vision and less dysphotopsias. Especially in a monovision setting, where the dominant eye is set for emmetropia and the other eye for low myopia is believe dto be a promising concept for spectacle independence.

Hence, the aim of this study is to compare a new monofocal IOL wit a non-diffractive extended depth of vision (Rayone EMV) with an already established non-diffractive EDOF IOL (Alcon Acrysof IQ Vivity) in a mini-monovision setting.

96 eyes of 48 patients will be included into this study. After randomization, each patient will either receive the Rayone EMV or the Alcon Acrysof IQ Vivity in both eyes. Follow-up visits will be 2 weeks and 3 months after surgery. During these visits a slitlamp examination, measurement of the intraocular pressure, visual acuity assessment, pupil size measurement, determination of the defocus curve, contrast sensitivity measurements, reading speed detection, and a flaremeter measurement will be performed.

Study Type

Interventional

Enrollment (Anticipated)

48

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Johannes Zeilinger, MD
  • Phone Number: 57564 01 91021
  • Email: office@viros.at

Study Contact Backup

  • Name: Natascha Bayer, MSc
  • Phone Number: 57564 01 91021
  • Email: office@viros.at

Study Locations

      • Vienna, Austria, 1140
        • Recruiting
        • Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital Vienna
        • Contact:
          • Johannes Zeilinger, MD
          • Phone Number: 57564 01 91021
          • Email: office@viros.at
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

17 years to 101 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • age-related bilateral cataract
  • age 21 or older
  • visual acuity > 0.05
  • axial length: 22.0 - 26.0 mm
  • normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
  • written informed consent prior to surgery

Exclusion Criteria:

  • active ocular disease (e.g. chronic severe uveitis, proliferative diabetic retinopathy, chronic glaucoma not responsive to medication)
  • relevant othe rophthalmic diseases such as pseudoexfoliation syndrome (PEX), intraoperative floppy iris syndrome (IFIS)
  • corneal decompensation or corneal endothelial cell insufficiency
  • previous ocular surgery or trauma
  • persons who are pregnant or nursing (pregnancy test will be taken in women of reproductive age)
  • corneal astigmatism > 1 dpt.
  • retinopathies

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Rayone EMV
Patient will receive the non-diffractive monofocal IOL during cataract surgery
Rayone EMV
Experimental: Acrysof IQ Vivity
Patient will receive the standard EDOF IOL during cataract surgery
Acrysof IQ Vivity

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Visual acuity at intermediate distance
Time Frame: 24 months
The visual acuity at the intermediate distance will be measured using ETDRS charts at a distance of 80 centimetres and compared between the two different IOLs
24 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Visual acuity at far distance
Time Frame: 24 months
The visual acuity at the far distance will be measured using ETDRS charts at a distance of 4 metres and compared between the two different IOLs
24 months
Visual acuity at near distance
Time Frame: 24 months
The visual acuity at the near distance will be measured using ETDRS charts at a distance of 40 centimetres and compared between the two different IOLs
24 months
Visual acuity in the defocus curve
Time Frame: 24 months
The visual acuity in the defocus curve will be measured using ETDRS charts at 4 metres with the patient wearing glasses in the power range of -3.5 to +1.0 diopters (presented in 0.5 dioptre steps) and will be compared between the two IOLs
24 months
Halometry
Time Frame: 24 months
The size of the halos depicted in degrees will be assessed using the aston halometer and will be compared between the two IOLs
24 months
Contrast sensitivity
Time Frame: 24 months
Contast sensitvity will be measured using the Optec Vision tester and will be compared between the two IOLs
24 months
Reading speed
Time Frame: 24 months
Reading speed will be assessed with teh Salzburg Reading Desk and will be compared between the two different IOLs
24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 3, 2022

Primary Completion (Anticipated)

January 3, 2023

Study Completion (Anticipated)

January 3, 2024

Study Registration Dates

First Submitted

January 3, 2022

First Submitted That Met QC Criteria

January 3, 2022

First Posted (Actual)

January 18, 2022

Study Record Updates

Last Update Posted (Actual)

January 18, 2022

Last Update Submitted That Met QC Criteria

January 3, 2022

Last Verified

January 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Rayner Performance

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cataract Senile

Clinical Trials on non-diffractive monofocal IOL

Subscribe